Healthcare
Stonegate Capital Partners Updates Coverage on GoHealth Amid Medicare Advantage Shift
GoHealth Inc. prioritizes retention and member quality over enrollment growth in a disciplined Medicare Advantage market, focusing on protecting its $925 million commissions receivable asset while investing in automation and AI for future efficiency.
New AI Tool Shows Promise for Early Lung Cancer Detection
A new artificial intelligence tool could significantly improve early detection of lung cancer, potentially increasing survival rates for a disease that remains the leading cause of cancer-related deaths worldwide.
Nephros Targets $25 Million Opportunity in Greater New York with New Regional Sales Leader
Nephros appoints Dana Cunningham as dedicated regional sales leader to accelerate growth in the Greater New York market, which it estimates represents a $25 million annual addressable opportunity for point-of-use filtration and services.
Soligenix Reports Positive Interim and Comparative Data for CTCL Treatment HyBryte
Soligenix announced consistent interim response rates from its phase 3 FLASH2 study and positive comparative results for HyBryte against Valchlor in cutaneous T-cell lymphoma, highlighting progress for a disease with limited treatment options.
10X Health Appoints Will Sliger as CMO to Drive Brand and Marketing for Precision Health Platform
10X Health names Will Sliger as Chief Marketing Officer to build the marketing engine behind its personalized health and performance platform, signaling a strategic push to scale its brand and go-to-market operations.
German Sports Nutrition Brand TNT Expands Amazon Presence with Performance Supplements
True Nutrition Technology (TNT) launches its German-made Creatine Monohydrate with Creapure and Synapsensause Pre-Workout on Amazon, marking a key step in U.S. expansion and offering consumers access to high-quality, lab-tested supplements.
ORGANA Liquid Oxygen Now Available on Amazon for U.S. Consumers
ORGANA International expands its digital marketplace presence by offering its Liquid Oxygen supplement on Amazon, tapping into growing consumer demand for convenient liquid wellness products.
HeartBeam Closes $10 Million Public Offering to Accelerate Cardiac Tech Commercialization
HeartBeam Inc. raised $10 million in a public offering to fund the commercialization of its FDA-cleared 12-lead synthesized ECG system and other cardiac technologies.
Two Neuroscientists Awarded 2026 Ralph L. Sacco Scholarships for Brain Health Research
The American Academy of Neurology and the American Heart Association have awarded $150,000 scholarships to Sarah Kettlety and Cali McEntee to study concussion recovery in children and the effects of exercise on brain aging, respectively.
Combination Strategies Reshape Precision Oncology as Lixte Advances First-in-Class PP2A Inhibitor
Lixte Biotechnology's LB-100, a first-in-class PP2A inhibitor designed to enhance chemotherapy and immunotherapy, exemplifies the industry shift toward combination regimens to overcome resistance in solid tumors.
Soligenix Gains EU Orphan Drug Designation for SGX945 in Behçet's Disease, Bolstering Rare Disease Pipeline
The European Commission granted orphan drug designation to Soligenix's SGX945 for Behçet's disease, validating the therapy's potential and supporting the company's rare disease strategy.
Cardio Diagnostics Holdings Gains Attention for AI-Driven Cardiovascular Platform
Cardio Diagnostics Holdings is highlighted as a company to watch due to its AI-powered approach to cardiovascular disease prevention, detection, and management, integrating epigenetics and genetics for personalized insights.
LIXTE Biotechnology Advances LB-100 as a Novel Cancer Treatment Enhancer
LIXTE Biotechnology's LB-100, a first-in-class PP2A inhibitor, aims to boost the effectiveness of existing chemotherapies and immunotherapies in hard-to-treat cancers, with ongoing clinical trials for ovarian, colon, and soft tissue sarcomas.
Soligenix Reports Encouraging Interim Data and Positive Comparative Results for CTCL Therapy
Soligenix released promising interim analysis from its phase 3 FLASH2 study and positive comparative results for HyBryte versus Valchlor, reinforcing its progress in developing treatments for cutaneous T-cell lymphoma.
Gallup Survey Reveals Growing Use of AI to Supplement Healthcare Visits
A Gallup and West Health survey found that many Americans are using AI tools to complement their healthcare interactions, with usage patterns varying by age, income, and motivation, highlighting implications for providers and policymakers.
Study Reveals AI Medical Diagnosis Errors Exceed 80%, Raising Safety Concerns
A new study finds that generative AI systems make diagnostic errors in over 80% of cases, highlighting significant limitations in reasoning for clinical use.
Half a Million Post-9/11 U.S. Veterans Have High Blood Pressure, Many Undiagnosed
A new study reveals that about half a million younger post-9/11 veterans have high blood pressure, with many undiagnosed or untreated, highlighting critical gaps in cardiovascular care.
HeartBeam Closes $10M Public Offering to Fund Commercialization of ECG Technology
HeartBeam raised $10 million in a public offering to advance its FDA-cleared 12-lead synthesized ECG system and heart attack detection technologies, positioning the company for expanded market reach.
Precision Oncology Shifts to Combination Strategies as Resistance Challenges Persist
Cancer treatment is increasingly moving toward multi-drug regimens that combine targeted therapies with immunotherapy and chemotherapy, with Lixte Biotechnology's first-in-class PP2A inhibitor LB-100 designed to enhance existing treatments by disrupting cancer cell repair and boosting immune activity.
Biotech Valuation Shift: Drug Pipeline Progress Now Measured as Financial Assets Under GAAP
The biotech sector is experiencing a transformation where advancing drug pipelines are increasingly valued as financial assets under fair-value accounting, with companies like Oncotelic Therapeutics exemplifying how clinical progress directly impacts balance sheet valuation.
Ocumetics Reports Life-Changing Six-Month Results from First-in-Human Study of Accommodating Intraocular Lens
Ocumetics Technology Corp. announced that six-month postoperative results from its first-in-human study of the Ocumetics Accommodating Intraocular Lens show continued vision improvements and meaningful quality-of-life enhancements for patients, with plans to advance to Group Two surgeries.
Helus Pharma CEO Steps Down, Co-founder Eric So Appointed Interim Chief
Helus Pharma announced the immediate resignation of CEO Michael Cola and appointment of co-founder Eric So as interim CEO, aiming to ensure continuity during a pivotal phase with upcoming Phase 3 trial results.
Lantern Pharma Seeks FDA Feedback on HARMONIC Trial Protocol Amendments for Lung Cancer Drug
Lantern Pharma has scheduled a Type C meeting with the FDA to discuss proposed changes to its Phase 2 HARMONIC trial for LP-300 in non-small cell lung cancer, focusing on EGFR Exon 21 L858R patients based on promising clinical data.
Aditxt Subsidiary's Protein Analysis Platform Shows Promise in Breast Cancer Treatment Study
A study published in npj Precision Oncology found that Ignite Proteomics' protein analysis platform provided more predictive insight into metastatic breast cancer treatment outcomes than traditional methods, potentially improving treatment selection.
Oragenics Reports Early Progress in Phase IIa Trial of Intranasal Concussion Therapy
Oragenics Inc. has enrolled two patients and administered eight doses in its Phase IIa trial for ONP-002, a potential first-in-class intranasal treatment for mild traumatic brain injury, addressing a significant unmet medical need in a market with no FDA-approved pharmacological therapies.
Soligenix CEO Advocates for Patient-Centric Reformulation Strategy in Rare Disease Drug Development
Soligenix CEO Christopher Schaber argues that reformulating therapies to better fit patients' daily lives can improve access, adherence, and long-term viability, highlighting a strategic shift in biopharmaceutical development.
MindBio Therapeutics Expands AI Intoxication Detection with New Data Collection Platform
MindBio Therapeutics has launched Intox Collect™, broadening its AI-driven intoxication detection capabilities beyond alcohol to include multiple central nervous system stimulants and depressants, with implications for workplace safety across high-risk industries.
Soligenix Gains European Orphan Drug Designation for Behçet's Disease Therapy SGX945
The European Commission granted orphan drug designation to Soligenix's SGX945 for treating Behçet's disease, validating the therapy's potential and providing regulatory and commercial incentives for development in a rare disease area with significant unmet need.
Cardio Diagnostics Holdings Leverages AI and Epigenetics for Advanced Cardiovascular Disease Management
Cardio Diagnostics Holdings is advancing cardiovascular disease prevention and detection through an AI-driven platform that integrates genetics and epigenetics to provide personalized insights.
LIXTE Biotechnology's LB-100 Represents Novel Cancer Treatment Approach Through PP2A Inhibition
LIXTE Biotechnology Holdings is advancing LB-100, a first-in-class PP2A inhibitor designed to enhance existing cancer therapies by making tumors more responsive to chemotherapy and immunotherapy in multiple clinical programs targeting solid tumors with significant unmet medical need.